Literature DB >> 28152483

LSD1 collaborates with EZH2 to regulate expression of interferon-stimulated genes.

Yue Jin1, Bo Huo1, Xueqi Fu1, Tian Hao1, Yu Zhang1, Yidi Guo1, Xin Hu2.   

Abstract

Histone methylation is a complicate and dynamic epigenetic modification that regulates gene transcription, chromosomal structure and cell differentiation. Here, we discovered the interaction between the H3K4 demethylase, lysine specific demethylase 1 (LSD1, an important component of CoREST repressor complex) and the H3K27 methyltransferase, enhancer of zeste homolog 2 (EZH2, an essential component of PRC2). Immuno-precipitation and GST-pull down assay were performed to observe the interaction between the proteins. The MCF-7 cells were cultured and transfected with the siRNA. The mRNA and proteins were examined by using the real-time polymerase chain reaction (RT-PCR) and western blot assay, respectively. HPLC and LC-MS/MS analysis were performed to purify the proteins. RT-PCR-based quantitative ChIP analysis were performed. LSD1 interacts with histone modification protein EZH2 in MCF-7 cells. LSD1 and EZH2 target a few common genes. LSD1 knockdown and EZH2 knockdown affect protein expression. LSD1 knockdown and EZH2 knockdown affect the proteins involving in IFN signaling pathway. LSD1 and EZH2 modify histone methylation at IRF9 gene locus. We systematically analyzed the proteins that are affected by either LSD1 or EZH2 knockdown with proteomic approaches and identified that the interferon pathway and some other pathways are commonly affected. The interaction between LSD1 and EZH2 stabilizes the binding of LSD1 to the promoter region of IRF9, which is a key transcription factor of the interferon pathway. In conclusion, our study revealed that the coordination between histone demethylases and methyl-transferases might serve as a double lock system to suppress the expression of interferon stimulated genes.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  EZH2; Histone modification; IRF9; Interferon pathway; LSD1

Mesh:

Substances:

Year:  2017        PMID: 28152483     DOI: 10.1016/j.biopha.2017.01.055

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  Epigenetic factor competition reshapes the EMT landscape.

Authors:  M Ali Al-Radhawi; Shubham Tripathi; Yun Zhang; Eduardo D Sontag; Herbert Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2022-10-10       Impact factor: 12.779

2.  SFMBT1 facilitates colon cancer cell metastasis and drug resistance combined with HMG20A.

Authors:  Ruijun Pan; Dingye Yu; Jiajia Hu; Xiao Yang; Chenxing Wang; Luyang Zhang; Pei Xue; Jing Sun; Xiaoping Zhang; Wei Cai
Journal:  Cell Death Discov       Date:  2022-05-16

3.  Long non-coding RNA SNHG15 inhibits P15 and KLF2 expression to promote pancreatic cancer proliferation through EZH2-mediated H3K27me3.

Authors:  Zhonghua Ma; Hesuyuan Huang; Jirong Wang; Yan Zhou; Fuxing Pu; Qinghong Zhao; Peng Peng; Bingqing Hui; Hao Ji; Keming Wang
Journal:  Oncotarget       Date:  2017-08-18

Review 4.  Long non-coding RNAs: crucial regulators of gastrointestinal cancer cell proliferation.

Authors:  Jiaxin Chen; Shuiping Liu; Xiaotong Hu
Journal:  Cell Death Discov       Date:  2018-04-27

5.  Theoretical analysis of Polycomb-Trithorax systems predicts that poised chromatin is bistable and not bivalent.

Authors:  Kim Sneppen; Leonie Ringrose
Journal:  Nat Commun       Date:  2019-05-13       Impact factor: 14.919

6.  PRC2 activates interferon-stimulated genes indirectly by repressing miRNAs in glioblastoma.

Authors:  Haridha Shivram; Steven V Le; Vishwanath R Iyer
Journal:  PLoS One       Date:  2019-09-12       Impact factor: 3.240

7.  PNSA, a Novel C-Terminal Inhibitor of HSP90, Reverses Epithelial-Mesenchymal Transition and Suppresses Metastasis of Breast Cancer Cells In Vitro.

Authors:  Aotong Zhang; Xin Qi; Fu Du; Guojian Zhang; Dehai Li; Jing Li
Journal:  Mar Drugs       Date:  2021-02-20       Impact factor: 5.118

8.  EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice.

Authors:  Lingling Wu; Xiaoyue Jiang; Chaojun Qi; Chunyan Zhang; Bo Qu; Nan Shen
Journal:  Front Immunol       Date:  2021-03-26       Impact factor: 7.561

9.  EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes.

Authors:  Taylor Harding; Jessica Swanson; Brian Van Ness
Journal:  Oncotarget       Date:  2018-04-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.